知识与财富的链接
摘要 目的：观察信迪利单抗注射液联合替吉奥和奥沙利铂（SOX）方案新辅助治疗局部进展期胃癌的临床疗效。方法：按照随机数字表法将徐州市肿瘤医院2022年1月至2023年6月期间接收的98例局部进展期胃癌患者分为对照组（SOX方案治疗,例数为49例）和研究组（对照组的基础上接受信迪利单抗注射液治疗,例数为49例）。对比两组疗效[客观缓解率（ORR）、疾病控制率（DCR）]、血清肿瘤标志物水平、T淋巴细胞亚群及不良反应发生率。结果：研究组的ORR、DCR较对照组更高（P<0.05）。研究组治疗后CEA、CA724、CA125、CD8+较对照组更低,CD4+、CD4+/CD8+较对照组更高（P<0.05）。研究组32.65%的不良反应发生率比对照组的28.57%更高,但两组比较无差异（P>0.05）。结论：信迪利单抗注射液联合SOX方案新辅助治疗局部进展期胃癌,可有效阻止疾病进展,降低血清肿瘤标志物水平,改善免疫功能。
ABSTRACT Objective: To observe the clinical efficacy of xindili monoclonal antibody injection combined with S-1 and oxaliplatin (SOX) regimen as neoadjuvant therapy for locally advanced gastric cancer. Methods: According to the random number table method, 98 patients with locally advanced gastric cancer received in Xuzhou Cancer Hospital from January 2022 to June 2023 were divided into control group (49 cases treated with SOX regimen) and study group (49 cases treated with xindili monoclonal antibody injection on the basis of control group). The efficacy [objective response rate (ORR), disease control rate (DCR)], serum tumor marker levels, T lymphocyte subsets and incidence of adverse reactions were compared between two groups. Results: In study group, the ORR and DCR were higher than those in control group(P<0.05). After treatment, CEA, CA724, CA125 and CD8+ in study group were lower than those in control group, CD4+ and CD4+/CD8+ were higher than those in control group(P<0.05). The incidence of adverse reactions in the study group was 32.65% higher than that in the control group, which was 28.57%, but there was no difference between the two groups(P>0.05). Conclusion: Xindili monoclonal antibody injection combined with SOX regimen neoadjuvant therapy for locally advanced gastric cancer, which can effectively prevent disease progression, reduce serum tumor marker levels, improve immune function.
